At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06938 RIBOLIFE-B
Closed 10-28 16:08:25
44.080
+1.700
+4.01%
High45.000Low40.520Vol178.21K
Open45.000D1 Closing42.380Amplitude10.57%
Mkt Cap7.45BTradable Cap7.45BTotal Shares169.00M
T/O7.78MT/O Rate0.11%Tradable Shares169.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
RIBOLIFE-B Spends HKD 2.11 Million to Repurchase 50,000 H-Shares, Outstanding Share Count Drops to 169.46 Million
Bulletin Express  ·  10-27 18:41
RIBOLIFE-B Spends HKD 2.11 Million to Repurchase 50,000 H-Shares, Outstanding Share Count Drops to 169.46 Million
Suzhou Ribo Life Science Files Next Day Disclosure Return with HKEX Announcing Share Buyback
Reuters  ·  10-27 18:37
Suzhou Ribo Life Science Files Next Day Disclosure Return with HKEX Announcing Share Buyback
Suzhou Ribo Life Science Files HKEX Next-Day Return Disclosing Share Buyback
Reuters  ·  10-23
Suzhou Ribo Life Science Files HKEX Next-Day Return Disclosing Share Buyback
RIBOLIFE-B Buys Back 37,200 H Shares, Treasury Stock Rises to 1.01 Million
Bulletin Express  ·  10-22
RIBOLIFE-B Buys Back 37,200 H Shares, Treasury Stock Rises to 1.01 Million
Suzhou Ribo Files Next-Day Disclosure with HKEX Announcing Share Buyback
Reuters  ·  10-21
Suzhou Ribo Files Next-Day Disclosure with HKEX Announcing Share Buyback
Ribo Life Science Buys Back 200 H Shares, Lifting Treasury Stock to 972,200 Units
Bulletin Express  ·  10-21
Ribo Life Science Buys Back 200 H Shares, Lifting Treasury Stock to 972,200 Units
Ribocure-B Shares Jump Over 9% Intraday on Plan to Acquire Remaining Stake in Ribocure Pharmaceuticals AB
Deep News  ·  10-20
Ribocure-B Shares Jump Over 9% Intraday on Plan to Acquire Remaining Stake in Ribocure Pharmaceuticals AB
Hong Kong Stock Announcements: Dongshan Precision Launches IPO, Li Auto Introduces External Equity Financing for Mahexin Technology via Capital Subscription Agreement
Stock News  ·  10-20
Hong Kong Stock Announcements: Dongshan Precision Launches IPO, Li Auto Introduces External Equity Financing for Mahexin Technology via Capital Subscription Agreement
Ribo Life Science to Boost Stakeholding in Biotech Company via Share Swap
MT Newswires Live  ·  10-19
Ribo Life Science to Boost Stakeholding in Biotech Company via Share Swap
Suzhou Ribo Proposes Bylaw Amendments to Reflect Registered Capital Increase
Reuters  ·  10-19
Suzhou Ribo Proposes Bylaw Amendments to Reflect Registered Capital Increase
Suzhou Ribo Life Science Co - to Buy Remaining 49.71% of Target Company
THOMSON REUTERS  ·  10-19
Suzhou Ribo Life Science Co - to Buy Remaining 49.71% of Target Company
Suzhou Ribo Life Science Co Ltd - Target Company Refers to Ribocure Pharmaceuticals Ab
THOMSON REUTERS  ·  10-19
Suzhou Ribo Life Science Co Ltd - Target Company Refers to Ribocure Pharmaceuticals Ab
Suzhou Ribo Life Science Co - Minority Shareholders to Receive 15 Consideration Shares Per Target Share
THOMSON REUTERS  ·  10-19
Suzhou Ribo Life Science Co - Minority Shareholders to Receive 15 Consideration Shares Per Target Share
Ribo Life-B (06938) Jumps Over 5% Intraday After EU Phase I Clinical Trial Application for RBD3133 Injection
Stock News  ·  10-08
Ribo Life-B (06938) Jumps Over 5% Intraday After EU Phase I Clinical Trial Application for RBD3133 Injection
Suzhou Ribo Submits EU Phase I Clinical Trial Application for Obesity siRNA Rbd3133
Reuters  ·  10-08
Suzhou Ribo Submits EU Phase I Clinical Trial Application for Obesity siRNA Rbd3133
Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of Inhbe-Targeting Sirna Rbd3133
THOMSON REUTERS  ·  10-08
Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of Inhbe-Targeting Sirna Rbd3133
Ribo Life-B Shares Rise Over 5% in Morning Trading as Company's Automated Intelligent Drug Screening Center Is Completed
Deep News  ·  09-29
Ribo Life-B Shares Rise Over 5% in Morning Trading as Company's Automated Intelligent Drug Screening Center Is Completed
RIBOLIFE-B Turns Profitable as Licensing Windfall Quadruples H1 Revenue; Cash Surges After Hong Kong IPO
Bulletin Express  ·  09-21
RIBOLIFE-B Turns Profitable as Licensing Windfall Quadruples H1 Revenue; Cash Surges After Hong Kong IPO
RIBOLIFE-B Repurchases 181,600 H-Shares; Treasury Holding Rises to 0.57% of Issued Capital
Bulletin Express  ·  09-16
RIBOLIFE-B Repurchases 181,600 H-Shares; Treasury Holding Rises to 0.57% of Issued Capital
Suzhou Ribo Life Science Files HKEX Next-Day Return Disclosing Share Buyback Held as Treasury Shares
Reuters  ·  09-11
Suzhou Ribo Life Science Files HKEX Next-Day Return Disclosing Share Buyback Held as Treasury Shares
No data available

Introduction

Company Name.
RIBOLIFE-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.
Issue price:
--